Drug Importers Can Defend VAT Refunds Despite BIR Format Objections

CTA denied the Commissioner’s bid to reverse a P104.1M VAT refund for imported prescription drugs, rejecting repeated format-based objections. Pharmaceutical importers seeking VAT refunds for prescription drugs should focus on proving the substantive basis of their exemption and preserving documentary evidence, because a refund should not be defeated merely by a repeated procedural objection that […]

RR No. 18-2020: VAT Exemption on Prescription Drugs and Medicines for Diabetes, Hypertension, High Cholesterol, Cancer, Mental Illness, Tuberculosis, and Kidney Diseases

RR No. 18-2020 clarifies VAT exemption for approved prescription medicines, key disease categories, effective dates, and import VAT refund rules. Manufacturers, distributors, wholesalers, retailers, importers, hospitals, pharmacies, and corporate taxpayers dealing in covered prescription medicines must immediately review their VAT treatment because RR No. 18-2020 confirms that certain drugs and medicines are VAT-exempt, but only […]

RMC No. 62-2020: VAT-Exempt Prescription Drugs for Diabetes, High Cholesterol and Hypertension Starting January 27, 2020

RMC No. 62-2020 lists VAT-exempt prescription drugs for diabetes, high cholesterol, and hypertension effective January 27, 2020. Pharmacies, hospitals, clinics, importers, distributors, and VAT-registered sellers must treat only the listed prescription drugs and medicines for diabetes, high cholesterol, and hypertension as VAT-exempt beginning January 27, 2020. The key business consequence of RMC No. 62-2020 is […]